Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 515 of 5804
-
Immunotherapy cocktail shows promise against tough rectal cancers
Disease control CompletedThe objective is to evaluate whether the neoadjuvant combination of tislelizumab (a PD-1 inhibitor) with interleukin-2 (IL-2) chemotherapy can significantly increase the Objective Response Rate (ORR) and the Pathological Complete Response rate (pCR) in patients with locally advan…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New weekly shot shows promise for major weight loss
Disease control CompletedThis is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidit…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Herbal cream could heal diabetic foot wounds without surgery
Disease control OngoingThis is a phase II/III seamless design, randomized, double-blind, paralleled-group, placebo-controlled study to evaluate the efficacy and safety of Xianglei Tangzu Gao for the treatment of Wagner grade II diabetic foot ulcers. The primary endpoint is the proportion of subjects wi…
Phase: PHASE2, PHASE3 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug trial hopes to shrink tumors in kids with Hard-to-Treat cancers
Disease control Recruiting nowSubstudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lympho…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New heart ablation device shows promise for common irregular heartbeat
Disease control CompletedThis clinical investigation is intended to demonstrate safety and effectiveness of the TactiFlex™ Ablation Catheter Sensor Enabled™, the Volt™ Pulse Field Ablation (PFA) Generator, and EnSite™ X EP System with EnSite™ Pulsed Field Ablation Software for the treatment of symptomati…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise for Hard-to-Treat stomach cancer
Disease control Recruiting nowThe safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects with HER2-expressing advanced/metastatic colorectal o…
Phase: PHASE2, PHASE3 • Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a daily pill after endometriosis surgery keep pain away?
Disease control Recruiting nowThe goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same sur…
Phase: PHASE3 • Sponsor: Main Line Health • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug hopes to ease sickle cell pain by boosting fetal hemoglobin
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in he…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo of radioactive drug and chemo tackles Hard-to-Treat breast cancer
Disease control OngoingIn the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative …
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Glow-in-the-dark dye helps surgeons spot hidden cancer during operations
Diagnosis Recruiting nowThis is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy …
Phase: PHASE1, PHASE2 • Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Frozen hope: new study offers fertility lifeline for young cancer patients
Disease control Recruiting nowOvarian tissue freezing is an ideal option for these patients as it can be performed immediately and does not need any time for ovarian stimulation. We hope we can develop this service in our locality to allow more young female cancer patients to have their fertility preserved.
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for BRCA pancreatic cancer? trial tests adding cisplatin to standard chemo
Disease control OngoingThis phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to …
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo aims to shrink penile cancer before surgery
Disease control Recruiting nowThis is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Magnetic bypass: a new tool to fight obesity and diabetes?
Disease control OngoingThe objective of the MagDI Australia Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversi…
Phase: NA • Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Targeted drug shows promise for rare Gene-Fueled cancers
Disease control Recruiting nowThe NRG1 gene is located on chromosome 8 (8p12 region) and encode NRG1. NRG1 gene is translated to generate six different proteins (I-VI) and at least 31 isoforms. NRG1 proteins are structurally related to EGF and contain an EGF-like motif that binds and activates ErbB3 and ErbB4…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Air force launches massive study to see if wingman training can prevent suicides
Prevention ENROLLING_BY_INVITATIONThis study involves collection of implementation data and analysis of USAF de-identified administrative data on base-level suicide attempt rates following US Air Force (USAF) delivery of Wingman-Connect training at 8 operational AF bases, as part of a force-wide scale out of the …
Phase: NA • Sponsor: University of Rochester • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise in tough pancreatic cancer trial
Disease control OngoingChiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Phase: PHASE2 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control CompletedThis is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Sweat-Powered relief: could a High-Tech suit drain fluid from heart failure patients?
Symptom relief Recruiting nowThe REFORM-HF study aims to test a new technology, AQUAPASS, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure. Patients will wear a lightweight suit that helps remove excess fluids through their sweat. The investigators want to see if the…
Phase: NA • Sponsor: AquaPass Medical Ltd. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat breast cancer
Disease control Recruiting nowThe study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC